NCT06983158View on ClinicalTrials.gov

A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

PHASE1/PHASE2SuspendedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 3, 2025

Primary Completion Date

December 20, 2028

Study Completion Date

December 20, 2028

Conditions
Developmental and Epileptic Encephalopathy
Interventions
DRUG

gene therapy

Intra-venous gene therapy

Trial Locations (4)

10021

Weill Cornell Medicine, New York

19146

Buerger Center for Advanced Pediatric Care, Children's Hospital of Philadelphia, Philadelphia

77030

Texas Children's Hospital, Houston

80045

Colorado Child Health Research Institute, Aurora

Sponsors
All Listed Sponsors
lead

Capsida Biotherapeutics, Inc.

INDUSTRY